Compare AEYE & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AEYE | MAIA |
|---|---|---|
| Founded | 2005 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 90.5M | 79.0M |
| IPO Year | 2011 | 2022 |
| Metric | AEYE | MAIA |
|---|---|---|
| Price | $7.12 | $1.28 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $14.63 | N/A |
| AVG Volume (30 Days) | 180.8K | ★ 553.8K |
| Earning Date | 05-12-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 30.56 | ★ 33.33 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $40,311,000.00 | N/A |
| Revenue This Year | $11.12 | N/A |
| Revenue Next Year | $11.45 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 14.52 | N/A |
| 52 Week Low | $5.31 | $0.87 |
| 52 Week High | $16.39 | $3.19 |
| Indicator | AEYE | MAIA |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 46.47 |
| Support Level | N/A | $1.25 |
| Resistance Level | N/A | $1.48 |
| Average True Range (ATR) | 0.00 | 0.07 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 0.00 | 26.32 |
AudioEye Inc is a software solution provider delivering immediate ADA and WCAG accessibility compliance at scale. Through patented technology, subject matter expertise and proprietary processes, it is eradicating all barriers to digital accessibility, helping creators get accessible and supporting them with ongoing advisory and automated upkeep. It helps everyone identify and resolve issues of accessibility and enhance user experiences, automating digital accessibility for the widest audiences. It generates revenue through the sale of subscriptions for software-as-a-service (SaaS). accessibility solutions.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of targeted immunotherapies for cancer, with an initial focus on non-small cell lung cancer (NSCLC), which represents the majority of lung cancer cases. Its asset, ateganosine (THIO, also known as 6-thio-dG or 6-thio-deoxyguanosine), is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The treatment approach involves administering THIO followed by the immune checkpoint inhibitor Libtayo (cemiplimab), which is manufactured and commercialized by Regeneron.